Natural product based leads to fight against leishmaniasis
- PMID: 24355247
- DOI: 10.1016/j.bmc.2013.11.048
Natural product based leads to fight against leishmaniasis
Abstract
The growing incidence of parasitic resistance against generic pentavalent antimonials, specifically for visceral disease in Indian subcontinent, is a serious issue in Leishmania control. Notwithstanding the two treatment alternatives, that is amphotericin B and miltefosine are being effectively used but their high cost and therapeutic complications limit their use in endemic areas. In the absence of a vaccine candidate, identification, and characterization of novel drugs and targets is a major requirement of leishmanial research. This review describes current drug regimens, putative drug targets, numerous natural products that have shown promising antileishmanial activity alongwith some key issues and strategies for future research to control leishmaniasis worldwide.
Keywords: Alkaloids; Drug targets; Leishmaniasis; MDR; Natural compounds.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis.Mini Rev Med Chem. 2018;18(1):26-41. doi: 10.2174/1389557517666170425105129. Mini Rev Med Chem. 2018. PMID: 28443518 Review.
-
Alkaloids: future prospective to combat leishmaniasis.Fitoterapia. 2009 Mar;80(2):81-90. doi: 10.1016/j.fitote.2008.10.009. Epub 2008 Oct 31. Fitoterapia. 2009. PMID: 19015012 Review.
-
Leishmaniasis: current status of available drugs and new potential drug targets.Asian Pac J Trop Med. 2012 Jun;5(6):485-97. doi: 10.1016/S1995-7645(12)60084-4. Asian Pac J Trop Med. 2012. PMID: 22575984 Review.
-
Screening natural products database for identification of potential antileishmanial chemotherapeutic agents.Interdiscip Sci. 2011 Sep;3(3):217-31. doi: 10.1007/s12539-011-0101-x. Epub 2011 Sep 29. Interdiscip Sci. 2011. PMID: 21956744
-
Leishmaniasis: drug resistance and natural products (review).Int J Mol Med. 2008 Sep;22(3):277-86. Int J Mol Med. 2008. PMID: 18698485 Review.
Cited by
-
Biological Profiling of Semisynthetic C19-Functionalized Ferruginol and Sugiol Analogues.Antibiotics (Basel). 2021 Feb 12;10(2):184. doi: 10.3390/antibiotics10020184. Antibiotics (Basel). 2021. PMID: 33673350 Free PMC article.
-
Nanomedicine-based strategies to improve treatment of cutaneous leishmaniasis.R Soc Open Sci. 2022 Jun 15;9(6):220058. doi: 10.1098/rsos.220058. eCollection 2022 Jun. R Soc Open Sci. 2022. PMID: 35719886 Free PMC article.
-
Dual-target drugs against Leishmania donovani for potential novel therapeutics.Sci Rep. 2023 Oct 26;13(1):18363. doi: 10.1038/s41598-023-45448-x. Sci Rep. 2023. PMID: 37884555 Free PMC article.
-
Investigational drugs for visceral leishmaniasis.Expert Opin Investig Drugs. 2015 Jan;24(1):43-59. doi: 10.1517/13543784.2014.954035. Epub 2014 Nov 20. Expert Opin Investig Drugs. 2015. PMID: 25409760 Free PMC article.
-
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.J Med Chem. 2018 Mar 22;61(6):2329-2352. doi: 10.1021/acs.jmedchem.7b01581. Epub 2018 Mar 6. J Med Chem. 2018. PMID: 29461823 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical